Protein Summary
This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation. Bradykinin, a 9 aa peptide, is generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. Two types of G-protein coupled receptors have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. The protein encoded by this gene is one of these receptors and is synthesized de novo following tissue injury. Receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
- ENST00000216629
- ENSP00000216629
- ENSG00000100739
- ENST00000611804
- ENSP00000479276
- BRADYB1
- B1R
- BKR1
- B1BKR
- BKB1R
- BDKRB2
- BRADYB1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
ligand (chemical) | 0.9 | ||
gene perturbation | 0.82 | ||
biological process | 0.81 | ||
virus perturbation | 0.72 | ||
biological term | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 214.49 (req: < 5)
Gene RIFs: 85 (req: <= 3)
Antibodies: 297 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 214.49 (req: >= 5)
Gene RIFs: 85 (req: > 3)
Antibodies: 297 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 613
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1